Trial Profile
A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 05 Sep 2019 Status changed from active, no longer recruiting to completed.
- 29 Aug 2019 This trial has been completed in France.
- 08 Aug 2019 Planned End Date changed from 23 Sep 2019 to 15 Aug 2019.